期刊文献+

他汀类药物临床研究进展 被引量:27

下载PDF
导出
摘要 随着社会发展、人民生活水平提高,心脑血管疾病发病率逐年升高。血脂异常是导致动脉粥样硬化的主要因素之一,与冠心病、高血压、脑卒中等疾病密切相关,因此,调脂药物已广泛应用于临床。目前应用最多的调脂药是羟甲基戊二酸单酰辅酶A(HMG-CoA)还原酶抑制剂(他汀)。他汀类药物拥有共同的药效基团,即二羟基庚酸基团,它对抑制HMG-CoA还原酶活性是必需的。
作者 孟锐 靳维华
出处 《中国现代医药杂志》 2011年第1期130-132,共3页 Modern Medicine Journal of China
  • 相关文献

参考文献16

  • 1Calabro P,Yeh TH.The pleiotropic effects of statins [J]. Curr Opin Cardiol,2005,20(6):541-546.
  • 2仝其广,胡大一.他汀类药物的安全性问题[J].中国实用内科杂志,2007,27(9):655-657. 被引量:64
  • 3鄢琳,曹立亚,雷建军,兰奋,李静,肖爱丽,邹燕,白雪,章渝,王超,张力文,李幼平.9种调血脂药物有效性及安全性评价[J].中国循证医学杂志,2005,5(1):8-21. 被引量:51
  • 4Giannotti G,Landmesser U.Endothelial dysfunction as an early sign of atherosclerosis[J]. Herz,2007,32(7):568-572.
  • 5Singh U,Devaraj S, Jialal L,et al. Comparison effect of atorvastatin (10 versus 80mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome.Am J Cardiol, 2008,102:321-325.
  • 6Liantonio A,Giannuzzi V,Cippone V,et al.Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mito chondfia Ca2+-release system.J Pharmacol Exp Ther,2007,321 (2): 626-634.
  • 7Liao JK,Laufs U. Pleiotropic effects of statins[J]. Annu Rev Pharmacol Toxicol,2005,45(1):89-118.
  • 8Watanabe T, Yasunari K,Nakamura M. Antioxidative actions of stations:Polertial mechanisms for antiathersclerotic effects[J].Mini Rev Med Chem,2006,6(5):505-508.
  • 9Fujiwara T, Saito S,Osanai T, et al. Decreased plasma and cardiac matrix metalloproteinase activities in patients with coronary artery disease and treated with pravastatin [J].Eur J Pharmaco,2008,594 (1-3):146-151.
  • 10Alsheikh-Ali AA, Maddukuri PV, Han H, et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes,rhab domyolysis,and cancer:insights from large randomized statin trials [J].J Am Coll Cardiol,2007,50(5):409-418.

二级参考文献94

  • 1金立仁,陈万春,胡伟国,包玉倩.阿西莫司的降脂效应[J].新药与临床,1993,12(5):297-298. 被引量:7
  • 2陈斌,韩琴琴,陈曙霞,梅尚义,胡义桥,陈淑良.吉非贝齐与非诺贝特降脂疗效比较[J].新药与临床,1995,14(2):77-79. 被引量:12
  • 3王家良.循证医学(第1版)[M].北京:人民卫生出版社,2001.5-50.
  • 4David Moher, Kenneth F Schulz, Douglas G Altman, for the CONSORT Group. The CONSORT statement: revised recommendations for improving the quality of reports of paralleo-group randomized trials [J]. TheLancet, 2001; 357(4): 1 191-1 194
  • 5Stalenhoef AF, Lansberg PJ, Kroon AA, Kortmann B, De Haan AF,Stuyt PM, Kastelein JJ. Treatment of primary hypercholesterolaemia.Short-term efficacy and safety of increasing doses of simvastatin and pravastatin: a double-blind comparative study [ J ]. J Intem Med,1993; 234(1): 77-82
  • 6The European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia ( multicountry comparative study) [J ]. Am J Cardiol, 1992; 70 ( 15 ): 1281 - 1 286
  • 7Lambrecht LJ, Malini PL. Efficacy and tolerability of simvastatin 20mg vs pravastatin 20 mg in patients with primary hypercholesterolemia.European Study Group[J]. Acta Cardiol, 1993; 48(6): 541 -554
  • 8Steinhagen-Thiessen E. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Simvastatin Pravastatin European Study Group [J ].Cardiology, 1994; 85(3-4): 244-254
  • 9The Simvastatin Pravastatin Study Group. Comparison of the efficacy,safety and tolerability of simvastatin and pravastafin for hypercholesterolemia[J]. Am J Cardiol, 1993; 71(16): 1 408-1 414
  • 10The Lovastatin Pravastatin Study Group, A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia[J]. Am J Cardiol, 1993; 71(10): 810 -815

共引文献134

同被引文献195

引证文献27

二级引证文献179

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部